扶正清毒法干预宫颈高危型HPV感染转归的临床研究  

Clinical Study on Outcome in High Risk HPV Infection of the Cervixthe with Fuzheng Qingdu Granule(扶正清毒颗粒)

作　　者：陈翊[1] 夏爱军[1] 周琴[1] 张燕[1] CHEN Yi;XIA Ai-jun;ZHOU Qin;ZHANG Yan(Kunshan Hospital of Traditional Chinese Medicine,Kunshan Jiangsu 215300,China)

机构地区：[1]昆山市中医医院,江苏昆山215300

出　　处：《中医药导报》2018年第21期53-56,共4页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：2015年昆山市社会发展科技项目(KS1555)

摘　　要：目的:采用郑氏经验方扶正清毒颗粒早期干预宫颈HR-HPV潜伏感染期、亚临床感染期及临床症状期,观察HPV感染的下降率、转阴率,并观察该方在治疗临床症状期的作用,能否阻止HPV感染的进展。方法:将处于潜伏期或亚临床症状期的患者分为治疗组和对照组,治疗组给予郑氏扶正清毒颗粒治疗,对照组不予处理。将处于临床症状期患者分为治疗组和对照组,治疗组给予郑氏扶正清毒颗粒+重组人干扰素α-2b栓治疗,对照组给予重组人干扰素α-2b栓治疗。服药疗程均为3个月,停药后1周内、3个月后、6个月后评价相应指标。结果:停止药物1周内,3个月后及6个月后的HPV病毒阴转率:第1部分研究治疗组分别为47.62%、78.57%、92.86%,对照组为26.83%、36.59%、41.46%,对应时间两组比较,差异均有统计学意义(P<0.05)。第2部分研究治疗组分别为46.79%、66.97%、80.73%,对照组为37.03%、48.15%、70.37%,对应时间两组结果比较,差异均有统计学意义(P<0.05)。第1部分和第2部分两组随着治疗的进行,HPV病毒载量均逐渐降低(P<0.05),且治疗组停药后1周内、3个月后、6个月后病毒载量均低于对照组相同时间点,差异均有统计学意义(P<0.05)。第2部分研究治疗组停止药物1周内、3个月后及6个月后的临床症状、体征积分与对应时间对照组结果比较,差异均有统计学意义(P<0.05)。所有患者均未发生明显不良反应。结论:郑氏经验方扶正清毒颗粒早期干预宫颈HR-HPV潜伏感染期及亚临床感染期效果显著;在重组人干扰素α-2b栓治疗基础上,加用扶正清毒颗粒,可以改善宫颈HR-HPV临床症状期感染转归。Objective： Fuzheng Qingdu granule（ 扶正清毒颗粒, FZQDG） was used to intervene cervical HR（high risk）-HPV infection at early stage to observe the decline rate and negative rate of HPV infection, and to observe the role of the prescription in the treatment of clinical symptoms, and whether it could prevent the progress of HPV infection. Methods： Patients in the incubation period or subclinical period were divided into treatment group and control group. The treatment group was treated with FZQDG, while the control group was not treated. The patients in clinical symptoms were divided into treatment group and control group. The treatment group was treated with FZQDG and recombinant human interferon α-2 b suppository, and the control group was treated with recombinant human interferon α-2 b suppository. Medication courses were 3 months, the corresponding indicators were evaluated within 1 week, 3 months, 6 months after medicines withdrawal. Results：The negative rate of HPV virus in 1 week, 3 months and 6 months after the medicines stopping was as follows：the first part of the treatment group were 47.62%, 78.57% and 92.86% respectively, while the control group was26.83%, 36.59% and 41.46%. The differences between the two groups at the corresponding time were statistically significant（P 0.05）. The second part of the treatment group were 46.79%, 66.97%, 80.73% and37.03%, 48.15%, 70.37% were in the control group, and the differences were statistically significant（P〈0.05）.The viral load of HPV in the first part and the second part decreased gradually with the treatment（P〈0.05）, and the viral load in the treatment group was lower than that in the control group within 1 week, 3 months and 6 months after withdrawal（P〈0.05）. In the second part, the scores of clinical symptoms and signs in the treatment group within 1 week, 3 months and 6 months after drug withdrawal were significantly different from those in the control group（P 0.05）. No adverse reactions occurred in all patient

关 键 词：扶正清毒颗粒 宫颈HR-HPV 感染转归 

分 类 号：R271[医药卫生—中医妇科学]